169 related articles for article (PubMed ID: 35082295)
1. Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma.
Martello M; Poletti A; Borsi E; Solli V; Dozza L; Barbato S; Zamagni E; Tacchetti P; Pantani L; Mancuso K; Vigliotta I; Rizzello I; Rocchi S; Armuzzi S; Testoni N; Marzocchi G; Martinelli G; Cavo M; Terragna C
Blood Cancer J; 2022 Jan; 12(1):15. PubMed ID: 35082295
[TBL] [Abstract][Full Text] [Related]
2. High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma.
Thakurta A; Ortiz M; Blecua P; Towfic F; Corre J; Serbina NV; Flynt E; Yu Z; Yang Z; Palumbo A; Dimopoulos MA; Gutierrez NC; Goldschmidt H; Sonneveld P; Avet-Loiseau H
Blood; 2019 Mar; 133(11):1217-1221. PubMed ID: 30692124
[TBL] [Abstract][Full Text] [Related]
3. The frequency and clinical outcome of mono-hit and multi-hit TP53 aberrations in newly diagnosed multiple myeloma.
Sreedharanunni S; Singla S; Balakrishnan A; Singh A; Jamwal M; Singh N; Singh C; Jandial A; Lad D; Sharma P; Sachdeva MUS; Malhotra P; Das R
Pathology; 2024 Jun; 56(4):556-564. PubMed ID: 38413253
[TBL] [Abstract][Full Text] [Related]
4. del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma.
Corre J; Perrot A; Caillot D; Belhadj K; Hulin C; Leleu X; Mohty M; Facon T; Buisson L; Do Souto L; Lannes R; Dufrechou S; Prade N; Orsini-Piocelle F; Voillat L; Jaccard A; Karlin L; Macro M; Brechignac S; Dib M; Sanhes L; Fontan J; Clement-Filliatre L; Marolleau JP; Minvielle S; Moreau P; Avet-Loiseau H
Blood; 2021 Mar; 137(9):1192-1195. PubMed ID: 33080624
[TBL] [Abstract][Full Text] [Related]
5. Minor clone provides a reservoir for relapse in multiple myeloma.
Magrangeas F; Avet-Loiseau H; Gouraud W; Lodé L; Decaux O; Godmer P; Garderet L; Voillat L; Facon T; Stoppa AM; Marit G; Hulin C; Casassus P; Tiab M; Voog E; Randriamalala E; Anderson KC; Moreau P; Munshi NC; Minvielle S
Leukemia; 2013 Feb; 27(2):473-81. PubMed ID: 22874878
[TBL] [Abstract][Full Text] [Related]
6. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma.
Lodé L; Eveillard M; Trichet V; Soussi T; Wuillème S; Richebourg S; Magrangeas F; Ifrah N; Campion L; Traullé C; Guilhot F; Caillot D; Marit G; Mathiot C; Facon T; Attal M; Harousseau JL; Moreau P; Minvielle S; Avet-Loiseau H
Haematologica; 2010 Nov; 95(11):1973-6. PubMed ID: 20634494
[TBL] [Abstract][Full Text] [Related]
7. Subclonal
Shah V; Johnson DC; Sherborne AL; Ellis S; Aldridge FM; Howard-Reeves J; Begum F; Price A; Kendall J; Chiecchio L; Savola S; Jenner MW; Drayson MT; Owen RG; Gregory WM; Morgan GJ; Davies FE; Houlston RS; Cook G; Cairns DA; Jackson G; Kaiser MF;
Blood; 2018 Dec; 132(23):2465-2469. PubMed ID: 30373884
[TBL] [Abstract][Full Text] [Related]
8. The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy.
Boyd KD; Ross FM; Tapper WJ; Chiecchio L; Dagrada G; Konn ZJ; Gonzalez D; Walker BA; Hockley SL; Wardell CP; Gregory WM; Child JA; Jackson GH; Davies FE; Morgan GJ;
Genes Chromosomes Cancer; 2011 Oct; 50(10):765-74. PubMed ID: 21961181
[TBL] [Abstract][Full Text] [Related]
9. Genetic alterations of TP53 and OTX2 indicate increased risk of relapse in WNT medulloblastomas.
Goschzik T; Mynarek M; Doerner E; Schenk A; Spier I; Warmuth-Metz M; Bison B; Obrecht D; Struve N; Kortmann RD; Schmid M; Aretz S; Rutkowski S; Pietsch T
Acta Neuropathol; 2022 Dec; 144(6):1143-1156. PubMed ID: 36181537
[TBL] [Abstract][Full Text] [Related]
10. Prognosis, Biology, and Targeting of
Flynt E; Bisht K; Sridharan V; Ortiz M; Towfic F; Thakurta A
Cells; 2020 Jan; 9(2):. PubMed ID: 31991614
[TBL] [Abstract][Full Text] [Related]
11. Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.
Svobodova K; Zemanova Z; Lhotska H; Novakova M; Podskalska L; Belickova M; Brezinova J; Sarova I; Izakova S; Lizcova L; Berkova A; Siskova M; Jonasova A; Cermak J; Michalova K
Leuk Res; 2016 Mar; 42():7-12. PubMed ID: 26851439
[TBL] [Abstract][Full Text] [Related]
12. TP53 mutation and survival in chronic lymphocytic leukemia.
Zenz T; Eichhorst B; Busch R; Denzel T; Häbe S; Winkler D; Bühler A; Edelmann J; Bergmann M; Hopfinger G; Hensel M; Hallek M; Döhner H; Stilgenbauer S
J Clin Oncol; 2010 Oct; 28(29):4473-9. PubMed ID: 20697090
[TBL] [Abstract][Full Text] [Related]
13. Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature.
Lionetti M; Barbieri M; Manzoni M; Fabris S; Bandini C; Todoerti K; Nozza F; Rossi D; Musto P; Baldini L; Neri A
Oncotarget; 2016 Apr; 7(16):21353-61. PubMed ID: 26870891
[TBL] [Abstract][Full Text] [Related]
14. The survival impact of CKS1B gains or amplification is dependent on the background karyotype and TP53 deletion status in patients with myeloma.
Hao S; Lu X; Gong Z; Bassett RL; Hu S; Konoplev SN; Tang G; Li S; Xu J; Khanlari M; Lee HC; Manasanch EE; Weber DM; Orlowski RZ; Medeiros LJ; Lin P
Mod Pathol; 2021 Feb; 34(2):327-335. PubMed ID: 32908255
[TBL] [Abstract][Full Text] [Related]
15. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.
Nadeu F; Delgado J; Royo C; Baumann T; Stankovic T; Pinyol M; Jares P; Navarro A; Martín-García D; Beà S; Salaverria I; Oldreive C; Aymerich M; Suárez-Cisneros H; Rozman M; Villamor N; Colomer D; López-Guillermo A; González M; Alcoceba M; Terol MJ; Colado E; Puente XS; López-Otín C; Enjuanes A; Campo E
Blood; 2016 Apr; 127(17):2122-30. PubMed ID: 26837699
[TBL] [Abstract][Full Text] [Related]
16. Gene abnormalities in multiple myeloma; the relevance of TP53, MDM2, and CDKN2A.
Elnenaei MO; Gruszka-Westwood AM; A'Hernt R; Matutes E; Sirohi B; Powles R; Catovsky D
Haematologica; 2003 May; 88(5):529-37. PubMed ID: 12745272
[TBL] [Abstract][Full Text] [Related]
17. Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients.
Shah V; Sherborne AL; Walker BA; Johnson DC; Boyle EM; Ellis S; Begum DB; Proszek PZ; Jones JR; Pawlyn C; Savola S; Jenner MW; Drayson MT; Owen RG; Houlston RS; Cairns DA; Gregory WM; Cook G; Davies FE; Jackson GH; Morgan GJ; Kaiser MF
Leukemia; 2018 Jan; 32(1):102-110. PubMed ID: 28584253
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.
Chiaretti S; Tavolaro S; Marinelli M; Messina M; Del Giudice I; Mauro FR; Santangelo S; Piciocchi A; Peragine N; Truong S; Patten N; Ghia EM; Torrente I; De Propris MS; Nanni M; Lawrence J; Guarini A; Foà R
Genes Chromosomes Cancer; 2011 Apr; 50(4):263-74. PubMed ID: 21319261
[TBL] [Abstract][Full Text] [Related]
19. Genomic characterization of functional high-risk multiple myeloma patients.
Soekojo CY; Chung TH; Furqan MS; Chng WJ
Blood Cancer J; 2022 Jan; 12(1):24. PubMed ID: 35102139
[TBL] [Abstract][Full Text] [Related]
20. Aberrant nuclear p53 protein expression detected by immunohistochemistry is associated with hemizygous P53 deletion and poor survival for multiple myeloma.
Chang H; Yeung J; Qi C; Xu W
Br J Haematol; 2007 Aug; 138(3):324-9. PubMed ID: 17555471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
